Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)

NCT02810444 is registered in ClinicalTrials.gov with Biotest as lead sponsor.

NCT NCT02810444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02810444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)
Lead sponsor
Biotest
Phase
Phase 3
Overall status
Completed
Start date
October 4, 2016
Completion date
April 1, 2020
Enrollment
81 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency disease